BAX BAXTER INTERNATIONAL INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 10456 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.3%
TTM net income YoY-112.0%
TTM EPS YoY-115.2%
Revenue 3-yr CAGR0.7%
Net income 3-yr CAGR—
Margins
Gross margin30.1%
Operating margin-1.9%
Net margin-6.2%
FCF margin—
EBITDA margin3.8%
Returns
ROE-10.5%
ROA-3.6%
ROIC (approx.)-3.5%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets66.6%
Debt / equity0.00x
Current ratio1.79x
Interest coverage-0.75x
Cash quality & payout
Operating cash flow / net income-2.27x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $11.24B | $10.64B |
| Cost of revenue | $7.87B | $6.65B |
| Gross profit | $3.38B | $3.98B |
| R&D expense | $518.00M | $590.00M |
| SG&A expense | $2.89B | $2.97B |
| Operating income | -$308.00M | $14.00M |
| Interest expense | $290.00M | $408.00M |
| Pretax income | -$505.00M | -$289.00M |
| Income tax | $395.00M | $37.00M |
| Net income | -$957.00M | -$649.00M |
| EBITDA | $673.00M | $1.01B |
| EPS (basic) | -1.87 | -1.27 |
| EPS (diluted) | -1.87 | -1.27 |
| Dividends declared per share | 0.52 | 1.04 |
| Weighted avg. shares (diluted) | 513.00M | 510.00M |
| Balance sheet | ||
| Cash & equivalents | $1.97B | $1.76B |
| Receivables | $1.86B | $1.68B |
| Inventory | $2.23B | $2.05B |
| Current assets | $6.87B | $8.85B |
| PP&E, net | $2.91B | $2.87B |
| Goodwill | $4.93B | $5.28B |
| Intangibles | $4.37B | $5.22B |
| Total assets | $20.05B | $25.78B |
| Current liabilities | $2.97B | $6.51B |
| Short-term debt | $1.00M | $2.13B |
| Long-term debt | $9.47B | $10.37B |
| Total debt | $9.47B | $12.50B |
| Total liabilities | $13.95B | $18.76B |
| Shareholders' equity | $6.13B | $6.96B |
| Net debt | $7.51B | $10.74B |
| Cash flow statement | ||
| Operating cash flow | $845.00M | $1.02B |
| Capital expenditure | $513.00M | $446.00M |
| Free cash flow | $332.00M | $573.00M |
| Investing cash flow | $2.84B | -$626.00M |
| Financing cash flow | -$4.22B | -$1.08B |
| Depreciation & amortization | $981.00M | $997.00M |
| Stock-based compensation | $117.00M | $114.00M |
| Dividends paid | $348.00M | $590.00M |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.